Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs SEA-BCMA (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 14 Nov 2018 According to a Seattle Genetics, Inc. media release, first patient has been dosed in this trial.
    • 20 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 31 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top